Chemical structure of molecule M5717 Merck Institute antimalarial compound

oral plasmodium eEF2 inhibitor

Ph. I candidate for malaria treatment

from phenotypic screen & optimization

The Lancet

Merck Institute for Pharmacometrics

13.   The Merck Institute antimalarial compound, M5717, is the first plasmodium eEF2 inhibitor to reach clinical development, and is a good example of an orally available dibasic compound as well…


 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.